Searchable abstracts of presentations at key conferences in endocrinology

ea0011p511 | Endocrine tumours and neoplasia | ECE2006

The latest safety and efficacy data of patients treated with Pegvisomant

Schreiber I , Forssmann K , Buchfelder M , Droste M , Mann K , Saller B , Strasburger CJ

The German Acrostudy is at present the largest database on acromegalics (n=184) treated with pegvisomant (Somavert®). 91% pts underwent pituitary surgery, 45% received radiation therapy, and previous medical therapy included dopamine agonists (56%), octreotide (90%) and/or lanreotide (10%). Common concomitant diseases at baseline were hypertension (47.0%), diabetes mellitus (31.7%), and gallstone disease (25.6%). Efficacy analysis was performed in 134 pt...